|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
PET/CT with prostate-specific membrane antigen (PSMA) ligands has shown high accuracy in detecting metastatic PCa lesions and could help assess response to therapy.
|
31693605 |
2020 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> PCA tissue samples revealed a wide range of PSMA staining intensity on IHC (IRS = 70-300) as well as in ARG (1.3%-22% of standard).
|
30737300 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this retrospective study, we investigated the impact of <sup>68</sup> Ga-PSMA-11 PET-CT (PSMA PET-CT) upon the treatment plan and therapeutic response obtained for Prostate Cancer (PCa) patients presenting an occult biochemical recurrence.
|
30549066 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel molecules such as PSMA-targeted small molecules promise theranostic agents in the management of PCa patients.
|
31353876 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine the diagnostic capabilities of combined prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and sentinel node (SN) biopsy in PSMA PET/CT negative patients for the primary lymph node (LN) staging in prostate cancer (PCa) patients.
|
31562222 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The pooled DR including 95% confidence intervals (95%CI) of PSMA-PET in restaging prostate cancer (PCa) patients was 72% (95%CI:60%-82%), increasing to 83% (95%CI:75%-90%) when PSAdt was ≤6 months and decreasing to 60% (95%CI:37%-80%) when PSAdt was >6 months, without a statistical significant difference.
|
30580449 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA-11 PET/CT is performed in our institution within an investigational new drug (IND) trial in PCa patients with biochemical recurrence (BCR).
|
29905907 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most promising candidates were additionally evaluated by small-animal PET in healthy rats using PSMA-positive peripheral ganglia as a model for small PCa lesions.
|
30389823 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasmas from prostate cancer (PCa) patient plasmas representing benign prostatic hyperplasia (BPH), low grade prostate cancer (Gleason Score 3 + 3) and high grade prostate cancer (Gleason Score ≥4 + 4) were analyzed for various exosome markers (CD9, CD63, CD81) and a prostate specific tissue marker (prostate specific membrane antigen/PSMA).
|
30680751 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to assess the diagnostic accuracy of radiolabeled prostate-specific membrane antigen positron emission tomography (PSMA PET) or positron emission tomography/computed tomography (PET/CT) for primary lymph node (LN) staging in newly diagnosed intermediate to high-risk prostate cancer (PCa) patients.
|
30269140 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Since the superiority of <sup>68</sup>Ga-PSMA-11 PET in detecting recurrent PCA is well established, the aim of our study was to assess its effect on management and outcome in all patients imaged during the first year after its introduction into clinical routine.
|
30488099 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA PET/CT and <sup>18</sup>F-NaF PET/CT showed comparable and high diagnostic accuracies for detecting bone metastases in PCa patients with BCR.
|
29876619 |
2018 |
|
Familial lichen amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aims of this study were to evaluate the association of intraprostatic <sup>68</sup>Ga-PSMA PET/CT findings and PSMA expression in immunohistochemical staining and generate a cutoff value for differentiation between normal prostate (PN) and PCA.
|
28775203 |
2018 |
|
Familial lichen amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively analysed all patients who underwent a staging <sup>68</sup>Ga-PSMA-11 PET/MRI scan between June 2016 and January 2018 for high-risk PCA, underwent radical prostatectomy in our institution, and gave written consent for further data analysis.
|
29523924 |
2018 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the diagnostic accuracy of <sup>64</sup>Copper prostate-specific membrane antigen (<sup>64</sup>Cu-PSMA) positron emission tomography/computed tomography (PET/CT) in the primary lymph node (LN) staging of a selected cohort of intermediate- to high-risk prostate cancer (PCa) patients.
|
28438628 |
2017 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prostate-specific membrane antigen (PSMA) is increasingly investigated as a novel tracer for gallium 68 PET/CT to detect PCa lesions in patients with recurrent disease.
|
28551611 |
2017 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Highly efficient gene delivery by this prostate cancer (PCA)-targeted J591/polyethylene glycol (PEG)/PEI/DNA-betagal vector was demonstrated in PSMA-positive cells relative to controls, resulting in significant growth inhibition in vitro when the J591/PEG/PEI/DNA-p53 was used.
|
16453011 |
2006 |